[ad_1]
Three other biotech companies have jumped on the Nasdaq, each raising more than $ 20 million more than their original targets as we begin to close a record year for biotech IPOs.
Seer, Sigilon Therapeutics and Silverback Therapeutics raised $ 175 million, $ 126 million and $ 241.5 million respectively, adding to the total pot of more than $ 13 billion this year.
Seer valued his offering of 9.2 million shares at $ 19 each, above a range of $ 16 to $ 18 set earlier this week. Biotech based in Redwood City, Calif., Initially forecasted a $ 150 million raise. It was started by CEO Omid Farokhzad, who left his post in a nanomedicine lab at Brigham and Women’s Hospital in Boston about two years ago to build a business around a technology that he said would change. the field of proteomics.
Keep Reading Endpoints With A Free Membership
Unlock this story instantly and join over 94,600 biopharmacy pros by reading Endpoints every day – and it’s free.
[ad_2]
Source link